Alterity Therapeutics Limited (ASX: ATH) - ETF Exposure

- Current share price for ATH : $0.450

Alterity Therapeutics Limited (ATH, formerly Prana Biotechnology Limited) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a clinical stage biotechnology company focused on neurodegenerative diseases. The company focusses to commercialise research into Parkinsonian movement disorders, Alzheimer disease, Huntington disease and other neurodegenerative disorders.

ATH General Information ⁺

ASX Code	ATH
Website	N/A
Industry/Sector	Biotechnology
Market Cap ($M)	103
ATH Share Price	$0.450
Day High	$0.455
Day Low	$0.435
Last Close	$0.450
ATH Share Price Movement	- ( No change )

Prices as at 16:40, 14 Sep 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to ATH

Alterity Therapeutics Limited (ATH) is held across 4 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when ATH moves, funds like MQYM, MQDB and MQIO that hold it can move with it.

For more concentrated exposure, ETFs such as MQYM (Macquarie Global Yield Maximiser Active ETF) allocate about 0.8% to ATH , while the average exposure across all 4 ETFs that hold it is around 0.3% .

Top ETF holdings

Macquarie Global Yield Maximiser Active ETF (MQYM) ~ 0.8%
Macquarie Dynamic Bond Active ETF (Managed Fund) (MQDB) ~ 0.2%
Macquarie Income Opp Active ETF (Managed Fund) (MQIO) ~ 0.1%

Last updated: ETF data and holdings as at 14 September 2026

Own ATH directly or through an ETF?

How does holding Alterity Therapeutics Limited (ATH) shares directly compare to ETFs that include it?

	ATH Direct	MQYM ASX	MQDB ASX	MQIO ASX
Holdings	1 company	71 holdings	205 holdings	348 holdings
ATH Weight	100%	0.8%	0.2%	0.1%
Diversification	Single Stock	Broad	Broad	Broad
Annual Cost	Brokerage only	0.59% p.a.	0.61% p.a.	0.49% p.a.
Approx. Yield	0%	6.71%	3.72%	4.57%
Star Ratings	-

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not ATH's direct yield. Annual cost uses each ETF's MER.

ATH Exposure on $10,000 investment

How a $10,000 investment in Alterity Therapeutics Limited (ATH) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Alterity Therapeutics Limited (ATH)	Direct share	$0.450	-9.09%	-$909	$9,091
Macquarie Global Yield Maximiser Active ETF (MQYM)	Fixed Income - Global	$49.190	-0.57%	-$57	$9,943
Macquarie Dynamic Bond Active ETF (Managed Fund) (MQDB)	Fixed Income - Global	$10.480	-0.85%	-$85	$9,915
Macquarie Income Opp Active ETF (Managed Fund) (MQIO)	Fixed Income - Global	$10.570	-0.19%	-$19	$9,981

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Alterity Therapeutics Limited (ATH) ETFs

4 ETFs hold Alterity Therapeutics Limited (ATH).

ETF	ATH Weight	MER	Yield
Macquarie Global Yield Maximiser Active ETF (MQYM)	0.8%	0.59%	6.71%
Macquarie Dynamic Bond Active ETF (Managed Fund) (MQDB)	0.2%	0.61%	3.72%
Macquarie Income Opp Active ETF (Managed Fund) (MQIO)	0.1%	0.49%	4.57%

View all 4 ETFs

Alterity Therapeutics Limited (ATH) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Alterity Therapeutics Limited (ATH) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Alterity Therapeutics Limited (ATH) price-sensitive announcements

ATH - Granted New U.S. Composition of Matter Patent for ATH434

Alterity Therapeutics Limited announced the granting of a new U.S. composition of matter p

Alterity Therapeutics Limited (ATH)
12 Aug 2026 | 8:36 AM

ATH - Quarterly Activities/Appendix 4C Cash Flow Report

Alterity Therapeutics Limited issued its Q4 FY26 Quarterly Activities and Appendix 4C Cash

Alterity Therapeutics Limited (ATH)
30 Jul 2026 | 10:00 AM

ATH - ATH Receives A$3.98m R&D Tax Incentive

Alterity Therapeutics Limited announced the receipt of A$3.98 million from the Australian

Alterity Therapeutics Limited (ATH)
9 Jul 2026 | 3:52 PM

ATH - FDA Meeting Minutes Confirm Registrational Path for ATH434

Alterity Therapeutics Limited announced that the FDA's official meeting minutes confirmed

Alterity Therapeutics Limited (ATH)
7 Jul 2026 | 9:44 AM

Alterity Therapeutics Limited (ATH) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Alterity Therapeutics Limited (ATH) ORDINARY FULLY PAID	Health Care	$103	Cleansing Notice Under Section 708A	8 Sep 2026 11:59AM	$0.485	$0.450	fallen by 7.22%
Alterity Therapeutics Limited (ATH) ORDINARY FULLY PAID	Health Care	$103	Application for quotation of securities - ATH	8 Sep 2026 11:41AM	$0.495	$0.450	fallen by 9.09%
Alterity Therapeutics Limited (ATH) ORDINARY FULLY PAID	Health Care	$103	Alterity to Present at Cantor Global Healthcare Conference	3 Sep 2026 9:26AM	$0.520	$0.450	fallen by 13.46%
Alterity Therapeutics Limited (ATH) ORDINARY FULLY PAID	Health Care	$103	Change of Director's Interest Notice - Stamler	2 Sep 2026 12:03PM	$0.505	$0.450	fallen by 10.89%
Alterity Therapeutics Limited (ATH) ORDINARY FULLY PAID	Health Care	$103	Change of Director's Interest Notice - Marks	2 Sep 2026 12:02PM	$0.505	$0.450	fallen by 10.89%
Alterity Therapeutics Limited (ATH) ORDINARY FULLY PAID	Health Care	$103	Application for quotation of securities - ATH	1 Sep 2026 2:54PM	$0.500	$0.450	fallen by 10%

ATH Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2028F	C2	-$0.10	0.00%	0.00%	0.0%
2027F	C2	-$0.10	-99.10%	0.00%	0.0%
2026A	-$23.40	-$11.10	-0.90%	0.00%	0.0%

ATH Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F
Alterity Therapeutics Limited (ATH)	$105M	-0.0089	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
CSL Limited (CSL)	$80,189M	0.7309	-0.4438	0.0545	10.3522	18.6122	17.6495	2.54%	2.49%	2.57%
Clinuvel Pharmaceuticals Limited (CUV)	$405M	-0.0696	-0.0719	0.0242	12.0359	12.9677	12.6614	0.62%	0.62%	0.62%
Mesoblast Limited (MSB)	$2,792M	-0.4380	0.0000	0.0000	0.0000	0.0000	341.2698	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,324M	-1.3893	0.0000	-0.9100	0.0000	150.0958	1,667.0213	0.00%	0.00%	0.00%

ATH Directors

Name	Position	Start Date
Dr David Stamler	Chief Executive Officer, Managing Director	21 Nov 2025
Mr Julian Barbaczy	Non-Executive Chairman, Non-Executive Director	21 Nov 2025
Mr Peter Ashley Marks	Non-Executive Director	29 Jul 2005
Mr Lawrence Bernard Gozlan	Non-Executive Director	8 Aug 2011
Ms Ann Cunningham	Non-Executive Director	17 Apr 2026

Alterity Therapeutics Limited (ATH) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
7 Apr 2025	GOZLAN, Lawrence	Buy	Indirect Shares	4,545,455	$0.011	$50,000.000
7 Apr 2025	MELTZER, Brian	Buy	Direct Shares	2,272,727	$0.011	$25,000.000
7 Apr 2025	MARKS, Peter	Buy	Indirect Shares	1,818,182	$0.011	$20,000.000

See all changes in directors' interest & trades for Alterity Therapeutics Limited (ATH) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

ATH Management

Name	Position
Abby Macnish Niven	Company Secretary

ATH Calendar of Events

Date	Event
27 August 2027	Report (Annual)
27 August 2027	Report (Prelim)
25 February 2027	Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us